MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Prothena Corp PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

6.27 -2.94

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.23

Max

6.62

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.2M

-60M

Pardavimai

705K

2.8M

Pelno marža

-2,128.536

Darbuotojai

163

EBITDA

-682K

-65M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+275.43% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-400M

346M

Ankstesnė atidarymo kaina

9.21

Ankstesnė uždarymo kaina

6.27

Naujienos nuotaikos

By Acuity

88%

12%

356 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Prothena Corp PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-18 21:01; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 20:46; UTC

Uždarbis

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025-07-18 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 20:36; UTC

Uždarbis

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025-07-18 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025-07-18 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 20:02; UTC

Rinkos pokalbiai

Gold Higher to Close Out Week -- Market Talk

2025-07-18 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025-07-18 19:06; UTC

Rinkos pokalbiai

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025-07-18 18:24; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025-07-18 18:19; UTC

Uždarbis

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025-07-18 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025-07-18 18:11; UTC

Uždarbis

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025-07-18 17:35; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025-07-18 16:29; UTC

Rinkos pokalbiai

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025-07-18 16:28; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 16:04; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025-07-18 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-18 15:58; UTC

Rinkos pokalbiai

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025-07-18 15:47; UTC

Rinkos pokalbiai
Uždarbis

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Akcijų palyginimas

Kainos pokytis

Prothena Corp PLC Prognozė

Kainos tikslas

By TipRanks

275.43% į viršų

12 mėnesių prognozė

Vidutinis 24.29 USD  275.43%

Aukščiausias 81 USD

Žemiausias 4 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Prothena Corp PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

4

Pirkti

4

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 7.35Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

356 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.